| |
| Names | |
|---|---|
| Preferred IUPAC name
2-Methoxy-1,7,9-trimethyl-7,9-dihydro-1H-purine-6,8-dione | |
| Other names
O(2),1,7,9-Tetramethylurate; Tetramethyluric acid; Dynamine
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C9H12N4O3 | |
| Molar mass | 224.22 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Methylliberine is an isolate of coffee beans, tea, cola nuts, guarana, cocoa, and yerba mate.[1] It is structurally related to Liberine.
Pharmacology
Pharmacodynamics
Based on its structural similarity to caffeine and theacrine methylliberine is widely believed to be an adenosine receptor antagonist, although as of 2023 no scientific studies have been done to confirm this action.[2] There is no evidence that methylliberine augments dopamine receptors in a way that is distinct from caffeine, contrary to claims made by manufacturer.[3][4]
Pharmacokinetics
Methylliberine has a short half-life of only 1.5 hours compared to the 5-7 hour half life of caffeine.[5] An interaction study showed concomitant administration of both caffeine and methylliberine increases the half-life of caffeine by about 2 fold.[5] This is likely due to inhibition of the CYP1A2 enzyme.[5] Safety studies of methyliberine have been conducted in rats and it is approved for use as a dietary supplement in the US.[6]
References
- ^ "Minor alkaloids in caffeine-containing beverages". Deutsche Lebensmittel-Rundschau. 96 (11): 363–368. 2000. Archived from the original on 2014-12-10. Retrieved 2013-10-16.
- ^ VanDusseldorp, Trisha A.; Stratton, Matthew T.; Bailly, Alyssa R.; Holmes, Alyssa J.; Alesi, Michaela G.; Feito, Yuri; Mangine, Gerald T.; Hester, Garrett M.; Esmat, Tiffany A.; Barcala, Megan; Tuggle, Karleena R.; Snyder, Michael; Modjeski, Andrew S. (28 February 2020). "Safety of Short-Term Supplementation with Methylliberine (Dynamine®) Alone and in Combination with TeaCrine® in Young Adults". Nutrients. 12 (3): 654. doi:10.3390/nu12030654. PMC 7146520. PMID 32121218.
- ^ Garrett, B. E.; Holtzman, S. G. (January 1994). "D1 and D2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats". Pharmacology, Biochemistry, and Behavior. 47 (1): 89–94. doi:10.1016/0091-3057(94)90115-5. ISSN 0091-3057. PMID 7906891. S2CID 23508010.
- ^ VanDusseldorp, Trisha A.; Stratton, Matthew T.; Bailly, Alyssa R.; Holmes, Alyssa J.; Alesi, Michaela G.; Feito, Yuri; Mangine, Gerald T.; Hester, Garrett M.; Esmat, Tiffany A.; Barcala, Megan; Tuggle, Karleena R.; Snyder, Michael; Modjeski, Andrew S. (2020-02-28). "Safety of Short-Term Supplementation with Methylliberine (Dynamine®) Alone and in Combination with TeaCrine® in Young Adults". Nutrients. 12 (3): 654. doi:10.3390/nu12030654. ISSN 2072-6643. PMC 7146520. PMID 32121218.
- ^ a b c Mondal, Goutam; Wang, Yan-Hong; Yates, Ryan; Bloomer, Richard; Butawan, Matthew (9 August 2022). "Caffeine and Methylliberine: A Human Pharmacokinetic Interaction Study: Original Research". Journal of Exercise and Nutrition. 5 (3). doi:10.53520/jen2022.103124.
- ^ Murbach, Timothy S.; Glávits, Róbert; Endres, John R.; Clewell, Amy E.; Hirka, Gábor; Vértesi, Adél; Béres, Erzsébet; Szakonyiné, Ilona Pasics (27 October 2019). "A Toxicological Evaluation of Methylliberine (Dynamine®)". Journal of Toxicology. 2019: 1–25. doi:10.1155/2019/4981420. PMC 6930730. PMID 31911801.
 | This article about an alkaloid is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 29 April 2024, at 18:31